INF	OR	иатю	ON DIS	CLOSL	JRE CIT	ATION	АТ	TY. DOC	KET N	D. PC2578	34A	SERIA	AL NO.	10/58	3,876
	(U	se se	veral sl	neets if	necess	ary)	AF	PLICAN	T Jus	tin Bryans	3				
							FIL	ING DA	TE Ja	anuary 29,	2007	GROL	JP	1624	
							U.S	S. PATEN	IT DOC	UMENTS					
EXAM INI	INER FIAL				DOC	CUMENT NU	MBER			DATE	NAME		CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
/D	R/	US	3	8	4	0	5	9	7	10-8-74	Moore, et a	al	260	556F	
H		US	4	2	3	3	2	9	9	11-11-80	Trummlitz, et	al	424	246	
		us	4	8	8	5	3	6	7	12-5-89	Yoshikawa, e	t al.	546	216	
		US	4	8	8	1	4	6	0	11-21-89	Bannister, et	al.	101	91	
		US	5	1	3	4	1	2	7	7-28-92	Rajewski, et Equiv to WO 94/0251	- 1	514	58	
		US	5	3	4	4	3	9	1	9-6-94	Reitz, et al		568	34	
		US	5	3	8	0	7	3	8	1-10-95	Talley, et a Equiv to WO 94/2798	30	548	235	
		US	5	4	4	8		5	4	5-23-95	Huang, et a Equiv. to WO 95/3065		542	342	
		US	5	4	6	6	8	2	3	11-14-95	Talley, et a Equiv to WO 95/1531		546	279	
		US	5	4	7	4	9	9	5	12-12-95	Ducharme, e Equiv to WO 95/0050		514	241	
		US	5	4	7	5	0	1	8	12-12-95	Bertenshaw, e Equiv to WO 95/1531		548	377.1	
		US	5	4	8	2	9	4	1	1-9-96	Terrett, et a Equiv to WO 93/1209		544	284	
		US	5	4	8	6	5	3	4	1-23-96	Penning, et a Equiv to WO 96/0338		548	375.1	
		US	5	5	9	1	7	4	2	1-7-97	Terrett, et a Equiv to WO 94/0566		544	119	
		US	5	6	2	0	9	9	9	4-15-97	Barta, et a Equiv. to WO 96/0338		548	334.5	
		US	5	5	2	4	2	9	7	5-28-96	Graneto, Matth	ew J.	514	406	
		US	5	5	8		5	7	5	8-20-96	Graneto, et Equiv. to WO 96/6093		548	359.5	
		US	5	5	٠	5		2	2	11-19-96	Kimura, et a Equiv. to WO 93/0712	al 24	514	259	
		us	5	5	9	6	0	0	8	1-21-97	Lee, Len F Equiv. to WO 96/2458	35	546	339	
V	/	US	5	6	1	6	6	0	1	4-1-97	Khanna, et : Equiv. to WO 96/0338		546	184	

Page 1 of 6 /Deepak Rao/ 09/18/2008

INFOR	MATIC	ON DIS	CLOSU	IRE CIT	ATION	АТ	TY. DOC	KET N	D. PC2578	34A	SERIAL NO	10/58	3,876
(L	lse se	veral sl	neets if	necess	ary)	AP	PLICAN	T Jus	tin Bryans	3			
						FIL	ING DA	TE Ja	anuary 29,	2007	GROUP	1624	
/DR/	us	5	6	3	3	2	7	2	5-27-97	Talley, et a Equiv. to WO 96/254	514	378	
	us	5	6	4	3	9	3	3	7-1-97	Graneto, et Equivalen WO 96/384	t 514 42	378	
	us	5	6	6	8	1	6	1	9-16-97	Collins, et a Equiv. to WO 96/033	548	194	
	us	5	6	7	0	5	1	0	9-23-97	Huang, et a Equiv, to WO 95/306			
	us	5	7	3	1	3	4	3	3-24-98	Feng, et al Equiv to WO 96/259:	514	450	
	us	5	7	3	4	0	5	3	3-31-98	Terrett, et a Equiv to WO 94/004	544	277	
	us	5	1	8	8	1	6	6	4-14-98	Li, et al Equiv. to WO 96/169		716	
	us	5	8	8	1	1	1	9	9-11-99	Fortin, et a Equiv. to WO 98/034	514	356	
	us	6	۰	3	2	5	9	9	8-3-99	Belley, et a	al 514	341	
	us	6	٠	4	5	5	3	9	8-31-99	Haruta, et	al 548	235	
	us	6	٠	5	е	۰	7	4	10-19-99	Kargman, et	al 514	461	
	us	6	٥	е	4	•	7	,	11-9-99	Belley, et a	al 514	473	
	us	6	٠	۰	4	3	7	9	11-30-99	Bayly, et a	514	367	
	us	5	9	9	4	9	8	1	11-30-99	Haruta, et : Equivalent JP905288	to	374	
	us	6	0	0	1	е	7	•	12-14-99	Dube, et a	514	277	
	us	6	0	0	2	0	7	4	12-14-99	Haruta, et	al 548	235	
	US	6	0	0	4	•	7	A	12-21-99	Blaschke, et	al 514	155	
	us	6	0	2	0	3	4	3	2-1-00	Belley, et a	al 514	309	
	US	6	0	2	е	2	9	2	2-22-00	Connolly, et	al 548	376.1	
	US	6	0	3	4	2	5	•	3-7-00	Carter, et a	al549	456	
	US	6	0	0	0	3	2_	8	3-21-00	Beers, et a	1 514	341	
	us	6	0	4	0	4	,	و	3-21-00	Davies, et	al 546	256	
	us	6	0	4	3	2	5	2	3-28-00	Bombrun, et	al 514	292	1-7
	us	6	0	4	6	2	1	7	4-4-00	Friesen, et	al 514	347	
	us	6	0	4	6	2	3	6	4-4-00	Hamanaka, e	atal 514	535	
V	us	6	0	5	7	3	1	9	5-2-00	Black, et a	514	242	

/Deepak Rao/

09/18/2008

NFOF	RMATIC	ON DIS	CLOSU	JRE CI	TATION	АТ	TY. DOC	KET N	O. PC2578	34A	SERIAL NO	. 10/588	3,876	
(1	Use se	veral s	heets if	necess	ary)	AP	PLICAN	T Jus	stin Bryans	3				
						FIL	ING DA	TE Ja	anuary 29,	2007	GROUP	1624		
/DR/	us	6	0	7	1	9	3	6	6-6-00	Dube, et al	514	334		
_	us	6	0	7	7	8	5	0	6-20-00	Carter, et a	514	311		
	us	6	0	7	7	8	6	8	6-20-00	Cook, et al	514	560		
	us	6	0	7	7	8	6	9	6-20-00	Sui, et al	514	615		
	us	6	0	8	0	8	7	6	6-27-00	Dorziotis, et	al 549	319		
	US	6	0	8	3	9	6	9	7-4-00	Ferro, et al	514	403		
	US	6	1	2	7	2	4	3	10-3-00	Pye, et al	549	286		
	us	6	7	3	3	3	3	4	10-10-00	Pye, et al	546	286		
_	us	6	1	3	3	2		2	10-17-00	Wang, et a	514	336		
_	us	6	1	3	3	2	3	3	10-24-00	Aotsuka, et	al 514	3 8 7		
	US	6	1	4	3	3		6	10-31-00	Chen, et al	549	324		
	US	6	1	4	3	4	8	6	11-7-00	Daugan, et	al 514	286		
	us	6	1	4	3	7	4	3	11-7-00	Freskos, et	al 514	253.11		
_	us	6	1	5	3	4	8	7	11-28-00	Rossen, et a	al 560	187		
	us	6	1	3	5	1	8	6	1-2-01	Belley, et a	549	336		
	us	6	1	2	ž	2	5	3	1-30-01	Nicolai, et a	il 514	336		
4	US	6	2	\$	4	3	8	7	3-20-01	Davies, et a	il 54 9	315		
_	US	6	2	2	2	2	4	3	4-24-01	Black, et al	549	60		
_	us	6	2	3	3	1	٠	7	5-29-01	Karmali, et a	al 514	274		
\perp	US	6	2	3	5	7	4	3	5-29-01	Wang, et a	514	473		
	us	6	2	5	1	9	0	4	6-26-01	Bunnage, et Eqivalent WO 99/5433	514	252.6		
	us	6	2	7	7	2	5	3	8-7-01	Carter, et a	1 514	432		
	us	6	2	7	4	5	9	0	8-14-01	Penning, et Eqivalent WO 94/1593	514	438		
	US	6	3	3	7	3	8	2_	10-2-01	Hartmann, et		603		
	US	6	3	2	2	3	5	3	10-3-00	Stevens, et	al 514	415		
	us	6	3	2	3	2	2	3	10-18-00	Nakao, et a	514	307		
İ	us	6	3	0	6	8	9	0	10-23-01	Kalgutkar, et	al 514	419		
	us	6	3	0	7	0	4	7	10-23-01	Black, et al Eqivalent WO 00/2471	544	240		
Ψ^-	us	6	3	1	0	0	7	9	10-30-01	Okumura, et		338		

INFO	ORM	IATIO	ON DIS	CLOSL	JRE CIT	ATION	АТ	TY. DOC	KET N	D. PC2578	34A	SERIAL NO.	10/58	3,876
	(Us	e se	veral sl	neets if	necess	ary)	AP	PLICAN	T Jus	tin Bryans	3			
							FIL	ING DA	TE Ja	anuary 29,	2007	GROUP	1624	
/DF	₹/	US	6	3	2	9	4	2	1	12-11-01	Prasit, et a	514	443	
		us	6	3	3	3	3	3	0	12-30-03	Bunnage, et Equivalent WO 00/247	514	258	
4	4	us	6	3	4	0	6	9	4	1-22-02	Joo, et al	514	337	
_		us	6	3	5	9	1	8	2	3-19-02	Stamler, et	al 568	949	
		us	6	3	6	2	1	7	8	3-26-02	Shenke, et a Equivalent WO 99/244	544	184	
		us	6	3	,	2	2	Ű	9	3-26-0	Haruta, et a	al 514	374	
_		us	6	3	9	9	2	1	•	4-9-02	Davies, et a	al 568	56	
		us	6	3	7	•	•	1	9	4-23-02	Reddy, et a	514	341	
		us	6	3	9	9	7	2	9	5-28-02	Judice, et a	ıl 514	183	
-		us	6	4	2	0	5	5	7	2-13-07	Storey, et a Equivalent WO 01/271	544	262	
		us	6	4	4	2	9	8	9	8-13-02	Lu, et al. Equivalent WO 96/384		375.1	
П														
		us	6	4	6	2	3	4	7	10-08-02	Bombrun, et Equivalent WO 00/156:	546	85	
		us	6	5	8	3	1	4	7	06-24-03	Kyun, et al Equivalent WO 00/278	514	262.1	
		us	6	4	2	3	4	4	9	2-4-04	Bunnage, et Equivalent WO 98/491	514	241	
		us	6	4	5	e	3	4	,	6-29-04	Allerton, et a Equivalent WO 01/271	546	276.1	
		us	6	4	4	0	•	4	,	8-3-04	Newman, et Equivalent WO02/0747	514	263.22	
		us	6	4	8	4	1	8	•	8-31-04	Allerton, et a Equivalent WO 02/0743	514	262.1	
		us	6	7	9	4	3	8	7	9-21-04	Allerton, et a Equivalent WO 02/0792	514	243	
000		us	6	8	2	5	1	9	7	11-30-04	Sawyer, et a Equivalent WO 02/006	544	343	
$ \sqrt{}$	٠	us	6	8	3	8	4	5	6	1-4-05	Gosmini, et a Equivalent	al. 546	64	

INFOR	MATIC	ON DIS	CLOSU	RE CIT	ATION	АТ	TY. DOC	KET NO	D. PC2578	34A	SERIAL NO	. 10/58	3,876	
(1	Jse se	veral sl	neets if	necessa	ary)	AP	PLICAN	Γ Jus	tin Bryans					
						FIL	ING DAT	ΓE Ja	nuary 29,		GROUP	1624		
										WO 02/288	59			_
/DR/	us	6	8	5	8	6	2	0	2-22-05	Shultze, et Equivalen WO 02/288	514	285		
***************************************	us	6	8	7	2	7	2	1	3-29-05	Sawyer, et : Equivalen WO 01/943	t l	250		
	us	6	8	7	8	7	1	1	4-12-05	Shultze, et a Equivalen WO 02/365	544	9	91	
	us	6	9	0	9	0		9	6-7-05	Shultze, et : Equivalen WO 02/006	544	343		
	us	6	9	1	1	5	8	2	6-28-05	Shultze, et a Equivalen WO 02/006	544	343		
	us	6	9	6	0	5	8	7	1-1-05	Shultze, et : Equivalen WO 02/385	544	345		
	us	6	9	6	•	•		à	8-11-05	Shultze, et : Equivalen WO 02/888	544	343		
	us	6	9	в	1	6	8	7	1-10-06	Gellibert, et Equivalen WO 03/0006	514	285		
	us	7	0	2	2	8	5	6	4-4-06	SAWUER, ei Equivalen WO 02/0648	514	292		
	us	7	0	3	4	0	2	7	4-25-06	Schultze, et Equivalen WO 02/101	544	343		
$\sqrt{}$	us	7	0	3	4	0	4	7	4-25-06	Junji, et al Equivalen WO 01/271	514	383		
						FORE	GN PAT	ENT DO	CUMENT	rs				
			DO	CUMENT NU	MBER				DATE	COUNTRY	CLASS	SUBCLASS	TRANSL	Αī
/DR/	EP	0	4	6	3	7	5	6	6-7-91	European	C07D	487/04		_
_	EP	0	5	2	6	0	0	4	7-2-92	European	C07D	487/04		_
\perp	EP	0	5	9	5	5	4	6	3-20-96	European	C07D	275/02		_
_	EP	0	7	9	9	8	2	3	2-4-97	European	C07D	207/32		_
\bot	EP	0	9	9	5	7	5	0	10-15-99	European	C07D	487/04		_
\bot	EP	0	9	9	5	7	5	1	10-15-99	European	C07D	487/04		_
	EP	1	0	9	2	7	1	8	10-20-00	European	C07D	473/30		_
<u>V</u>	EP	1	0	9	2	7	1	9	10-10-00	European	C07D	487/04		
ge 5 of	6		1995	onak Ra						09/18/20	08			

/Deepak Rao/

			CLOSU						D. PC2578		SERIAL NO	. 10/58	8,876	
(1	Use se	eral s	heets if	necessa	ary)		PLICAN		tin Bryans					
						FIL	ING DA	TE Ja	nuary 29,	2007	GROUP	1624		
/DR/	EP	1	2	4	1	1	7	0	9-18-02	European	C07D	487/14		
	EP	1	2	9	3	5	0	3	3-19-03	European	C07D	249/08		
	JP	0	0	0	6	3	3	6 3	8-12-98	Internationa	I C07D	249/08	yes	
	wo	9	3	0	6	1	0	4	4-1-93	Internationa	I C07D	487/04		
Т	wo	9	3	0	7	1	4	9	4-15-93	Internationa	I C07D	487/04		
	wo	9	5	1	9	9	7	8	7-27-95	Internationa	_	471/14		
	wo	۰		1		•			4-17-97	Internationa	I C07D	231/12		
T	wo	9	3	1	3		9	٥	10-29-98	Internationa		311/58		
	wo	0	0	1				е	3-2-00	Internations		31/4985		
T	wo	0	0	2	3		,	,	4-27-00	Internationa		311/58		
V	wo	0	0	3	5	2	9	8	6-22-00	Internationa		3/30		
			ОТНІ	R DO	UMEN	TS (Inc	luding A	uthor, T		Pertinent Pag				
/DR/		Patent Application Publication No. US2003/153575, Pub. Date 8-14-03, Bombum, et al., Equivalent to WO 01/94347 Patent Application Publication No. US2002/006443, Pub. Date 1-17-02, Babcock, et al.,												
\perp		Equivalent to WO 01/47495												
		Patent Application Publication No. US2002/150616, Pub. Date 1-17-02, Vandecruys, et al., Equivalent to WO 98/55148												
		Patent Application Publication No. US2002/173502, Pub. Date 9-19-02, Allerton, et al., Equivalent to WO 02/82597												
		Patent Application Publication No. US2004/0067945, Pub. Date 4-8-04, Niewohner, et al., Equivalent to WO 99/24433												
		Carter, J., et al. Expert Opinion on Therapeutic Patents, "Recently reported inhibitors of cyclooxygenase-2", Vol. 8(1), pgs. 21-29												
т		(1997) Coco, A.S., American Family Physician, "Primary dysmenorrhoea", Vol. 60, Pgs. 489-96 (1999).												
П		Finnin, et al., <u>Journal Pharm Science</u> , 'Transdermal Penetration Enhancers': Applications, Limitations, and potential', Vol. 88 (10) 055.058 (1000)												
T		955-956, (1999) Kaikefuda, et al., <u>Bigorganic & Medicinal Chemistry</u> . "Discovery of 4,5-Diphenyl-1,2,4-trizole Derivatives as a Novel Class Selective antagonists for the Human V _M , Receptor, Vol. 10, pg. 1905-1912, (2002)												
\sqcap		Kake	fuda, et a	I., Journa	l of Medic	inal Che	mistry, "S	ynthesis a	nd Pharmac	ological evaluation	on of 5-4(4-Bipheor", Vol. 45, pg.	eny)-3-meth 2589-2598.	yl-4-phi (2002)	
										ral drug deliver s				
		Rotel	la, et al., itial Agent	Journal o	f Medicinatment of E	al Chemi rectile D	istry, "N-3 Dysfunction	-Substitut	ed Imidazoq	uinazolinones: Po 263, (2000)	tent and Selecti	ve PDE5 In	hibitors	
			oeder, et a							and pelvic pain ir	adolescents*, \	/ol. 46, Pgs.	555-71	
		Verm	a etal., P	harmaceu	rtical Tech	nology	On-line, "D	Orug delive	ry technolog	ies and future di	ections", Vol. 25	i(2), 1-14,(2	001).	
\mathbf{V}														

Conforms with FORM PTO-FB-A820 INFORMATION DISCLOSURE